Clinical trials for Lung cancer
294 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 3
Lung cancer
#NCT06345729
#2023-507776-42-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
KRAS G12C
Required PDL1 statuses
PDL1 Positive (>= 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
7 recruiting sites
Merck Sharp & Dohme LLC
Phase 3
Lung cancer
#NCT06203210
Required histologic types
SCLC (Small Cell Lung Cancer)
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at localized stage
Chemotherapy
Required previous treatments at advanced or metastatic stage
Chemotherapy
12 recruiting sites
Daiichi Sankyo
Phase 3
Lung cancer
#NCT06417814
#2024-511362-37-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Non-squamous NSCLC
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
EGFR
Required number of previous lines of therapy for current stage of disease
1
2
Required previous treatments at advanced or metastatic stage
Targeted therapy
Excluded previous treatments at localized stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Immunotherapy
Chemotherapy
14 recruiting sites
AstraZeneca
Phase 3
Lung cancer
#NCT05984277
#2023-503298-39-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Squamous NSCLC
Non-squamous NSCLC
Required disease stage
Metastatic
Required PDL1 statuses
PDL1 Negative (< 1%)
PDL1 Positive (1% <= X < 25%)
PDL1 Positive (25% <= X < 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK
EGFR
ROS-1
1 recruiting site
AstraZeneca
Phase 3
Lung cancer
#NCT06908993
#2024-519971-25-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
MET
Required number of previous lines of therapy for current stage of disease
1
2
Required previous treatments at advanced or metastatic stage
Immunotherapy
Chemotherapy
Excluded genetic anomalies
ALK
BRAF
EGFR
HER2
KRAS non G12C
RET
ROS-1
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Targeted therapy
32 recruiting sites
Intergroupe Francophone de Cancérologie Thoracique
Phase 3
Lung cancer
#NCT06793215
#2024-518365-10-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Non-squamous NSCLC
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
KRAS G12C
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
14 recruiting sites
Hoffmann-La Roche
Phase 3
Lung cancer
#NCT06765109
#2024-517553-26-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
ALK
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
BRAF
EGFR
HER2
HRAS
KRAS G12C
KRAS non G12C
MET
NTRK-1/2/3
RET
ROS-1
Excluded previous treatments at advanced or metastatic stage
Targeted therapy
11 recruiting sites
Nuvalent Inc.
Phase 3
Lung cancer
#NCT07005128
#2024-520050-38-00
Required histologic types
SCLC (Small Cell Lung Cancer)
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Amgen
Phase 3
Lung cancer
#NCT06767514
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Squamous NSCLC
Non-squamous NSCLC
Required disease stage
Metastatic
Required PDL1 statuses
PDL1 Positive (>= 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK
BRAF
EGFR
HER2
HRAS
KRAS G12C
KRAS non G12C
MET
NTRK-1/2/3
RET
ROS-1
9 recruiting sites
Summit Therapeutics
Phase 3
Lung cancer
#NCT06758401
#2024-517968-36-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required PDL1 statuses
PDL1 Positive (>= 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK
BRAF
EGFR
MET
NTRK-1/2/3
RET
ROS-1
14 recruiting sites
Pfizer